Ghia P, Pluta A, Wach M, et al. ASCEND phase 3 study of acalabrutinib vs investigator’s choice of rituximab plus idelalisib (IdR) or bendamustine (BR) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). 24th Congress of EHA, abstract LB2606.
Itacitinib-monotherapie: veilig en effectief alternatief bij laagrisico acute GVHD
nov 2022 | Leukemie, Lymfoom, MDS, MPN, Stamceltransplantatie